CCCC ▲ +2.4% - C4 Therapeutics, Inc. $CCCC - C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting C4 Therapeutics rose 2.4% on news that the company will present biomarker data from a Phase 1 trial of its drug candidate cemsidomide combined with dexamethasone at the International Myeloma Society Annual Meeting. The presentation of clinical trial data, particularly immunomodulatory effects in a blood cancer indication, typically attracts investor interest in early-stage biotech companies. 03-SEP-2026 07:00 AM ET